Results 91 to 100 of about 3,635,661 (309)

Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancer

Molecular Oncology, EarlyView.
Comprehensive analysis of genomic mutations, gene expression, DNA methylation, and pathway analysis of TCGA data was carried out to define cancer types in which proteasome subunits expression is associated with worse survival. Albeit the effect of specific proteasome subunits on cellular function, the main role of the proteasome is better evaluated ...
Ruba Al‐Abdulla, Simone Venz, Ruslan Al‐Ali, Martin Wendlandt, Mandy Radefeldt, Elke Krüger   +5 more
wiley   +1 more source

The OMACS-PIL study: a randomised controlled trial within the OMACS observational study

Trials, 2019
Background There has been little research to investigate whether the appearance of paper patient information leaflets (PILs) used to describe research studies to potential participants influences their decision to take part.
Lucy Culliford, Rachel Brierley, Madeleine Clout, Rebecca Evans, Rachel Maishman, Dawn Phillips, Hana Tabusa, Barney Reeves, Chris A. Rogers   +8 more
doaj   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Correction to: Clinical trial recruiters’ experiences working with trial eligibility criteria: results of an exploratory, cross-sectional, online survey in the UK

Trials, 2021
William J. Cragg, Kathryn McMahon, Jamie B. Oughton, Rachel Sigsworth, Christopher Taylor, Vicky Napp   +5 more
doaj   +1 more source

Data‐driven discovery of gene expression markers distinguishing pediatric acute lymphoblastic leukemia subtypes

Molecular Oncology, EarlyView.
This study investigates gene expression differences between two major pediatric acute lymphoblastic leukemia (ALL) subtypes, B‐cell precursor ALL, and T‐cell ALL, using a data‐driven approach consisting of biostatistics and machine learning methods. Following analysis of a discovery dataset, we find a set of 14 expression markers differentiating the ...
Mona Nourbakhsh, Nikola Tom, Anna Schrøder Lassen, Helene Brasch Lind Petersen, Ulrik Kristoffer Stoltze, Karin Wadt, Kjeld Schmiegelow, Matteo Tiberti, Elena Papaleo   +8 more
wiley   +1 more source

Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance

Systematic Reviews
Our previous guide to estimating hazard ratios (HRs) from published summary (aggregate) data has become very widely used, but many still have difficulties knowing when and how to apply the methods.
Jayne F. Tierney, Sarah Burdett, David J. Fisher   +2 more
doaj   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

Molecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi   +11 more
wiley   +1 more source

Clinical Trials in Surgery

The Annals of African Surgery, 2014
A randomized clinical trial (RCT) is a type of experimental study where participants are randomly assigned to separate groups that compare different treatments (1).
Mwachaka P.M., James Kigera
doaj  

Three-outcome designs for external pilot trials with progression criteria

BMC Medical Research Methodology
Background Whether or not to progress from a pilot study to a definitive trial is often guided by pre-specified quantitative progression criteria with three possible outcomes.
Duncan T. Wilson, Eleanor Hudson, Sarah Brown   +2 more
doaj   +1 more source

Group sequential designs for negative binomial outcomes

, 2018
Count data and recurrent events in clinical trials, such as the number of lesions in magnetic resonance imaging in multiple sclerosis, the number of relapses in multiple sclerosis, the number of hospitalizations in heart failure, and the number of ...
Friede, Tim, Glimm, Ekkehard, Mütze, Tobias, Schmidli, Heinz   +3 more
core   +1 more source